Evidence map›Paper›PMID 39223354›Full record

ArticleJournal of nephrology2025

α-Klotho is associated with cardiovascular and all-cause mortality in patients with stage 3b and 4 chronic kidney disease (CKD): a long-term prospective cohort study.

Ludmila Yu Milovanova, Kirill S Nezhdanov, Svetlana Yu Milovanova, Marina V Lebedeva, Vladimir D Beketov, Alexey V Volkov, Elena S Kamyshova, Aleksandr Yu Suvorov, Sergey V Moiseev

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ludmila Yu MilovanovaSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation. Ludm.milovanova@gmail.com.ORCID 0000-0002-5599-0350
Kirill S NezhdanovLomonosov Moscow State University, Leninskie Gory, Moscow, 119991, Russian Federation.ORCID 0000-0001-9558-363X
Svetlana Yu MilovanovaSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation.ORCID 0000-0002-2687-6161
Marina V LebedevaSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation.ORCID 0000-0002-5923-1837
Vladimir D BeketovSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation.ORCID 0000-0002-6377-0630
Alexey V VolkovSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation.ORCID 0000-0002-1873-0189
Elena S KamyshovaSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation.ORCID 0000-0002-1823-0125
Aleksandr Yu SuvorovSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation.ORCID 0000-0002-2224-0019
Sergey V MoiseevSechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya st., Moscow, 119991, Russian Federation.ORCID 0000-0002-7232-4640

Funding

Russian Science Foundation 14-15-00947 2014
6 · The paper itself

Abstract

backgroundα-Klotho deficiency may increase cardiovascular risks and worsen survival. We evaluated the association of α-Klotho with cardiovascular and all-cause mortality in pre-dialysis chronic kidney disease (CKD) patients.

methodsIn this prospective study, 75 non-diabetic CKD stage 3b-4 patients were followed-up for a median of 8 years. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Human soluble α-Klotho ELISA Assay (IBL-Takara 27,998-96Well), Human Fibroblast Growth Factor-23 ELISA Assay (intact FGF23, Merck Millipore MILLENZ FGF23-32 K), and Human Sclerostin ELISA kits (Biomedica, Vienna, BI-20492) were used to measure serum α-Klotho, FGF23 and sclerostin levels in the certified laboratory at the Sechenov University according to the manufacturers' protocols. All patients underwent echocardiography to evaluate left ventricular mass index (LVMI), left ventricular ejection fraction by Simpson method, and cardiac (valve) calcification score by a semi-quantitative point scale. Lateral abdominal radiography by Kauppila method was used to estimate calcification of the abdominal aorta. Cox multivariate regression and receiver-operating characteristic curve (ROC)-analysis were used to evaluate risk factors for death and their cut-off values.

resultsPrimary and secondary endpoints were reached in 15 (20%) and 9 (12%) patients, respectively. Median α-Klotho levels in deceased and surviving patients were 344 and 484 pg/ml, respectively (p = 0.002). In a multivariate Cox regression model, baseline α-Klotho levels (HR 0.99, 95% CI 0.98-1.00, p = 0.023), aortic calcification (HR 1.18, 95% CI 1.02-1.36, p = 0.029) and left ventricular mass index (LVMI) (HR 1.04, 95% CI 1.00-1.08, p = 0.033) were associated with the primary endpoint, whereas α-Klotho (HR 0.99, 95% CI 0.98-1.00, p = 0.029), aortic calcification (HR 1.23, 95% CI 1.07-1.42, p = 0.003) and LVMI (HR 1.04, 95% CI 1.00-1.08, p = 0.021) were associated with the secondary endpoint. α-Klotho levels had the highest area under the curve (AUC) by ROC analysis, that is, 0.766 (95% CI 0.70-0.82) for the primary endpoint and 0.842 (95% CI 0.79-0.90) for the secondary endpoint with cut-off values of 412 pg/ml (HR 3.06, 95% CI 1.36-6.89, p = 0.007) and 368 pg/ml (HR 4.84, 95% CI 1.59-14.73, p = 0.005), respectively.

conclusionIn pre-dialysis CKD patients, α-Klotho levels are associated with all-cause and cardiovascular mortality and may be considered an early prognostic marker.

Indexed as

Cardiovascular DiseasesGlucuronidaseRenal Insufficiency, ChronicAdaptor Proteins, Signal TransducingAgedBiomarkersCause of DeathFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansKlotho ProteinsMaleMiddle AgedProspective StudiesRisk FactorsAdaptor Proteins, Signal TransducingBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsKL protein, humanSOST protein, humanCardiovascular mortalityChronic kidney diseaseα-Klotho

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.